Dr Robert Hasserjian is Professor of Pathology at Harvard Medical School and a Hematopathologist at Massachusetts General Hospital and is Program Director of the Mass General Brigham Hematopathology Fellowship. He received his MD from Harvard and trained in Anatomic Pathology and Hematopathology at Brigham and Women's Hospital. His research interests are in the discovery of pathologic and genetic features that impact the biology of myeloid and lymphoid neoplasms, particularly myelodysplastic syndromes and acute myeloid leukemia. Dr Hasserjian is an author of over 300 peer-reviewed publications, reviews, and chapters. He is a past President of the Society for Hematopathology. He was a pathology leader of the International Consensus Classification of Myeloid Neoplasms (2022) and serves as an expert panel member for the European LeukemiaNet AML Guidelines. He was also a leader of the Myeloid Classification Advancement Meeting (CAM) in 2026. Dr Hasserjian is strongly committed to advancing diagnosis and education in hematopathology and has lectured on the diagnosis bone marrow disorders at numerous courses and international meetings across the Americas, Europe, and Asia.

Consultant Haematologist, King’s College Hospital, London, UK Honorary Senior Clinical Lecturer, King’s College London, London, UK Clinical Interests: Aplastic anaemia (AA) and bone marrow failure syndromes, PNH, MDS and myeloid malignancies. Leads the King’s National Paroxysmal Nocturnal Haemoglobinuria service and National AA referral centre @ King’s. Translational Research: Molecular/immunological pathogenesis of MDS and aplastic anaemia, particular focus on overlap disorders. Bloodwise foundation and British Society of Haematology (BSH) senior clinical research fellow. Clinical Trials: Passionate about delivery of clinical trials. Current National/Global Coordinating Investigator for a number of early/late phase clinical trials. Current drive is to bring novel therapies for PNH, AA, TP53 mutated myeloid neoplasms and improvement of thrombocytopenia. Scienticific advisor/Patron for patient advocacy group (MDS UK) and member of the MDS NCRN working group. Secretary of the EBMT Severe Aplastic Anaemia Working Party. Vice-Chair of ASH Scientific Committee on Bone Marrow Failure. Chair of the MDS Special Interest Group (SIG) of BSH. Co-Chair of UK VEXNET (VEXAS National MDT panel). Vice Chair EHA Specialised Working Group on Genetic Predisposition to Blood Cancer (Rare diseases) Associate Editor of British Journal of Haematology and eJHaem. Editorial Board Member of Haematologica. Authored/co-authored over 220 articles in peer-reviwed journals and has contributed to book chapters in major textbooks.

Anna is a laboratory haematologist and clinical lead at the Department of Pathology and Laboratory Medicine, Auckland City Hospital. Her interests include myeloid and lymphoid malignancies, bone marrow failure and education.